About Optimo Medical
Optimo Medical was a Healthcare company founded in 2015. It delivers digital software for cornea detection in healthcare settings. It operates on a B2B model. Optimo Medical has raised $1.95 million across 2 funding rounds from investors including European Union. The company is recorded as dissolved. Its focus areas include Medical Technology, Diagnostic Software and Ophthalmology. Its competitors include Olympic Ophthalmics, 2EyesVision, Radius XR, Binovi and Myopia and 4 more; 1 of its 9 listed competitors has raised funding.
Company details
Optimo Medical, established in 2015, excels in providing healthcare solutions, medical technology, diagnostic software, and ophthalmology. Delivers digital software for cornea detection in healthcare settings. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
- SectorsHealthcare
- Website optimo-medical.com
- Social X Facebook
- Total Equity Funding$1.95M (USD)
in 2 rounds
- Latest Funding Round$1.95M (USD), Seed
Oct 2021
- Investors
Funding Insights of Optimo Medical
Optimo Medical has successfully raised a total of $1.95M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.95 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.95M
- Total Rounds 2
- Last Round Seed — $1.95M
- First Round $370,749
(Jan 2018)
- Investors Count 1
All 2 funding rounds of Optimo Medical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $1.95M | Seed | – | – | – |
| Jan 2018 | $370,749 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Optimo Medical
Optimo Medical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Optimo Medical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Optimo Medical
3 dated milestones of Optimo Medical across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Optimo Medical is founded.
- Funding First funding round of $371K.
- Funding Latest funding round, Seed, of $2.0M.
Competitors of Optimo Medical
Optimo Medical has 9 listed competitors in our database, 1 of them funded. They include Olympic Ophthalmics, 2EyesVision, Radius XR, Binovi and Myopia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| olympicophthalmics.com | 2020 | Issaquah, United States | – | – | Provider and developer of tear production device for treatments of dry eye disease | |
| 2eyesvision.com | 2015 | Madrid, Spain | $100,000 | – | Portable technologies for multifocal eye corrections before surgeries are developed. | |
| radiusxr.com | 2017 | Pleasanton, United States | – | – | Provider of wearable patient engagement and diagnostic system | |
| binovi.com | 2011 | Oakville, Canada | – | – | Provides software-based solutions for vision therapy plan to optometry professionals and patients | |
| myopia.app | 2018 | Aguilas, Spain | – | – | Myopia prevention app monitors family screen habits and distances. | |
| ioptima.com | 2005 | Caesarea, Israel | – | – | Ophthalmic therapeutics, including laser applications and eye drops, are developed. | |
| ocumetra.com | 2020 | Dublin, Ireland | – | – | Provider of myopia treatment analytics software | |
| neurapy.com | 2018 | Chennai, India | – | – | Provides software for vision therapy to treat eye issues at home and clinics. | |
| anteo.io | 2016 | New York, United States | – | – | SaaS-based vision therapy tool for providers |
Detailed competitors of Optimo Medical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
10 companies that operate in the same segment as Optimo Medical (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Optimo Medical
Complete news archive for Optimo Medical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Optimo Medical
Optimo Medical was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Optimo Medical is a funded company, having raised a total of $1.95M across 2 funding rounds to date. The company's 1st funding round was a Grant of $370.75K, raised on Jan 2018.
Optimo Medical, established in 2015, excels in providing healthcare solutions, medical technology, diagnostic software, and ophthalmology. Delivers digital software for cornea detection in healthcare settings. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
Optimo Medical's top competitors include 2EyesVision, Myopia and Radius XR.
Optimo Medical has 1 investor. Key investors include European Union.